CTSO Projected Dividend Yield

Cytosorbents Corp ( NASDAQ : CTSO )

Cytosorbents is engaged in the treatment of life-threatening conditions in the intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology. Co. has several products commercialized and in development based on this technology platform. CytoSorb, Co.'s primary product, is approved in the European Union as an extracorporeal cytokine absorber, designed to reduce the cytokine storm that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis.

20 YEAR PERFORMANCE RESULTS